Amgen Inc. (NASDAQ: AMGN) has reported lower revenues and adjusted earnings for the first quarter of 2023. The biotechnology firm also provided guidance for fiscal 2023.
![](data:image/svg+xml;charset=utf-8,<svg height="2156px" width="1280px" xmlns="http://www.w3.org/2000/svg" version="1.1"/>)
Unadjusted earnings decreased to $3.98 per share in the March quarter from $4.25 per share in the year-ago period. The reported net income was $2.84 billion or $5.28 per share in the latest quarter, compared to $1.48 billion or $2.68 per share in the same period of last year.
Total revenues edged down by 2% from last year to $6.11 billion during the three-month period. A 2% increase in product sales was more than offset by a decline in Other Revenue from the company’s COVID-19 manufacturing collaboration.
